Does Concomitant Psychostimulants Mitigate Second-Generation Antipsychotics-Associated Weight Gain? An Observational Study Based on Electronic Medical Records Data.

IF 1.5 4区 医学 Q2 PEDIATRICS
Ning Lyu, Paul J Rowan, Tyler J Varisco, Susan Abughosh, Ying Lin, Hua Chen
{"title":"Does Concomitant Psychostimulants Mitigate Second-Generation Antipsychotics-Associated Weight Gain? An Observational Study Based on Electronic Medical Records Data.","authors":"Ning Lyu, Paul J Rowan, Tyler J Varisco, Susan Abughosh, Ying Lin, Hua Chen","doi":"10.1089/cap.2024.0135","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> Weight loss is a well-documented adverse effect of psychostimulants. Given their frequent coprescription with second-generation antipsychotics (SGA) in pediatric patients, this study aims to examine whether concomitant use of psychostimulants mitigates SGA-associated weight gain in children and adolescents. <b><i>Method:</i></b> This study utilized the IQVIA Ambulatory electronic medical record-U.S. database (2016-2021) to identify patients aged 6-17 years who initiated an SGA. Those who started psychostimulants within 7 days of SGA initiation and maintained ≥90 days of use were classified as concomitant users, while those who initiated psychostimulants later with ≥90 days of overlap were add-on users. Patients never prescribed psychostimulants were SGA-only users. After adjusting for the baseline covariates using propensity scores, 6- and 12-month body mass index (BMI) <i>z</i>-score trends following psychostimulant initiation were compared between (1) concomitant and SGA-only users and (2) add-on and SGA-only users, using a linear mixed-effects regression model. <b><i>Results:</i></b> The results of linear mixed effect regression models indicate that concomitant users experienced a 0.0143 less monthly BMI <i>z</i>-score increase (<i>p</i> = 0.0063) compared with the SGA-only users over the 6 months following psychostimulant initiation. Similarly, add-on users had a significantly lower rate of weight gain compared with SGA-only users (<i>β</i> = -0.0463, <i>p</i> < 0.0001). When the follow-up period was extended to 12 months, the sensitivity analyses for both concomitant and add-on users were consistent with their primary analyses. <b><i>Conclusions:</i></b> Concomitant and add-on psychostimulants appear to mitigate SGA-associated weight gain in children and adolescents. Further investigation is needed to understand their effectiveness and safety relative to other interventions for antipsychotic-associated weight gain.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of child and adolescent psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cap.2024.0135","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Weight loss is a well-documented adverse effect of psychostimulants. Given their frequent coprescription with second-generation antipsychotics (SGA) in pediatric patients, this study aims to examine whether concomitant use of psychostimulants mitigates SGA-associated weight gain in children and adolescents. Method: This study utilized the IQVIA Ambulatory electronic medical record-U.S. database (2016-2021) to identify patients aged 6-17 years who initiated an SGA. Those who started psychostimulants within 7 days of SGA initiation and maintained ≥90 days of use were classified as concomitant users, while those who initiated psychostimulants later with ≥90 days of overlap were add-on users. Patients never prescribed psychostimulants were SGA-only users. After adjusting for the baseline covariates using propensity scores, 6- and 12-month body mass index (BMI) z-score trends following psychostimulant initiation were compared between (1) concomitant and SGA-only users and (2) add-on and SGA-only users, using a linear mixed-effects regression model. Results: The results of linear mixed effect regression models indicate that concomitant users experienced a 0.0143 less monthly BMI z-score increase (p = 0.0063) compared with the SGA-only users over the 6 months following psychostimulant initiation. Similarly, add-on users had a significantly lower rate of weight gain compared with SGA-only users (β = -0.0463, p < 0.0001). When the follow-up period was extended to 12 months, the sensitivity analyses for both concomitant and add-on users were consistent with their primary analyses. Conclusions: Concomitant and add-on psychostimulants appear to mitigate SGA-associated weight gain in children and adolescents. Further investigation is needed to understand their effectiveness and safety relative to other interventions for antipsychotic-associated weight gain.

伴随精神兴奋剂是否能减轻第二代抗精神病药物相关的体重增加?基于电子病历数据的观察性研究
目的:体重减轻是一种有充分证据的精神兴奋剂的不良反应。鉴于儿童患者经常与第二代抗精神病药物(SGA)共同用药,本研究旨在探讨精神兴奋剂的合用是否能减轻儿童和青少年与SGA相关的体重增加。方法:本研究利用IQVIA门诊电子病历系统。数据库(2016-2021),以确定6-17岁开始SGA的患者。在SGA开始使用后7天内开始使用精神兴奋剂并持续使用≥90天的患者被归类为伴随使用者,而在SGA开始使用后超过90天的患者被归类为附加使用者。从未开过精神兴奋剂处方的患者仅使用sga。在使用倾向评分调整基线协变量后,使用线性混合效应回归模型,比较(1)合用和仅使用sga的患者以及(2)附加和仅使用sga的患者在使用精神兴奋剂后6个月和12个月的体重指数(BMI) z-score趋势。结果:线性混合效应回归模型的结果表明,在精神兴奋剂开始使用后的6个月内,与仅使用sga的用户相比,同时使用sga的用户每月BMI z-score增幅减少0.0143 (p = 0.0063)。同样,与仅使用sga的用户相比,附加用户的体重增加率显着降低(β = -0.0463, p < 0.0001)。当随访期延长至12个月时,对伴随治疗和附加治疗患者的敏感性分析与他们的初步分析一致。结论:伴随和附加的精神兴奋剂似乎可以减轻儿童和青少年与sga相关的体重增加。需要进一步的研究来了解它们相对于其他抗精神病相关体重增加的干预措施的有效性和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.60
自引率
5.30%
发文量
61
审稿时长
>12 weeks
期刊介绍: Journal of Child and Adolescent Psychopharmacology (JCAP) is the premier peer-reviewed journal covering the clinical aspects of treating this patient population with psychotropic medications including side effects and interactions, standard doses, and research on new and existing medications. The Journal includes information on related areas of medical sciences such as advances in developmental pharmacokinetics, developmental neuroscience, metabolism, nutrition, molecular genetics, and more. Journal of Child and Adolescent Psychopharmacology coverage includes: New drugs and treatment strategies including the use of psycho-stimulants, selective serotonin reuptake inhibitors, mood stabilizers, and atypical antipsychotics New developments in the diagnosis and treatment of ADHD, anxiety disorders, schizophrenia, autism spectrum disorders, bipolar disorder, eating disorders, along with other disorders Reports of common and rare Treatment Emergent Adverse Events (TEAEs) including: hyperprolactinemia, galactorrhea, weight gain/loss, metabolic syndrome, dyslipidemia, switching phenomena, sudden death, and the potential increase of suicide. Outcomes research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信